There is no product in the shopping cart, buy it!
Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we can provide the novel prostate-specific antigen (PSA) detection service for the diagnostic of prostate cancer for our clients all over the world.
Prostate cancer is the second most common cancer as well as the fifth leading cause of cancer-associated mortality in men worldwide. Using a combination of surgery, radiation therapy, hormone therapy, or chemotherapy, tumors confined to the prostate may be curable. It was observed that if prostate cancer can be diagnosed early, most prostate cancers can be treated and cured, otherwise, metastasis will occur.
Prostate-specific antigen (PSA), also known as gamma-selenoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme secreted by prostate epithelial cells. It is a normal component of the ejaculate. In general, small quantities of PSA can be observed in the serum of healthy men but are often elevated in patients with prostate cancer or other prostate disorders. In this case, PSA can be served as the biomarker against prostate cancer.
Fig 1. Detection of triglycerides and PSA in serum samples of prostate cancer.1, 2
Detection of PSA in serum has been served as the promising method for the diagnostic of prostate cancer at an early and intervenable stage. Research data showed that PSA screening has little effect on prostate cancer-specific mortality, but it may increase the detection rate of prostate cancer at any stage.
Using our ELISA kit, PSA detection can be accomplished easily. Our sandwich ELISA method allows the formation of an antibody-analyte sandwich complex in one step, which significantly reduces the detection time. What’s more, the alternative PSA testing, percent-free PSA, and PSA velocity are also perfected as supplements.
In summary, PSA detection is beneficial for the diagnosis of prostate cancer, but it is still necessary to pay attention to potential short-term and long-term harms, including complications of biopsy and subsequent treatment, and the risk of overdiagnosis and overtreatment.
Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.
References